FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity
Karineh Kazazian(University of Toronto), Carol J. Swallow(Princess Margaret Cancer Centre), Karina Pacholzyk(Lunenfeld-Tanenbaum Research Institute), Wendy Johnston(University of Toronto), Deanna Ng(Mount Sinai Hospital), Julie Tan(Lunenfeld-Tanenbaum Research Institute), Michelle Chae Min Lee(Lunenfeld-Tanenbaum Research Institute), Hannah Sun-Tsi Wu(University of Toronto), Alannah Smrke(Lunenfeld-Tanenbaum Research Institute), Minji Kim(Lunenfeld-Tanenbaum Research Institute), Roland Xu(Lunenfeld-Tanenbaum Research Institute), F. Zih(University of Toronto), Aaron Pollett(Mount Sinai Hospital), Yosr Z. Haffani(Centre National de la Recherche Scientifique)
Cited by 34
Related Papers
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2020|482
Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers
|Nature Genetics|2015|379
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
|Annals of Surgical Oncology|2021|243
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma
|Annals of Surgery|2022|138
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
|Nature Communications|2021|64